Concepts (219)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Graft Rejection | 11 | 2020 | 1766 | 2.26 | Why? |
| Kidney Transplantation | 19 | 2021 | 5397 | 1.98 | Why? |
| Erythropoietin | 2 | 2020 | 167 | 1.40 | Why? |
| Graft Survival | 5 | 2019 | 587 | 1.34 | Why? |
| Immunosuppressive Agents | 11 | 2020 | 6331 | 1.12 | Why? |
| Monitoring, Immunologic | 3 | 2018 | 153 | 0.92 | Why? |
| Receptors, Erythropoietin | 2 | 2019 | 10 | 0.91 | Why? |
| Transplantation Immunology | 2 | 2021 | 99 | 0.90 | Why? |
| Glomerulonephritis | 2 | 2020 | 226 | 0.83 | Why? |
| Erythropoiesis | 1 | 2020 | 71 | 0.81 | Why? |
| Transplant Recipients | 7 | 2021 | 4982 | 0.80 | Why? |
| Immediate-Early Proteins | 1 | 2019 | 44 | 0.79 | Why? |
| HLA Antigens | 4 | 2021 | 830 | 0.77 | Why? |
| Regenerative Medicine | 2 | 2019 | 161 | 0.77 | Why? |
| Isoantibodies | 3 | 2018 | 134 | 0.76 | Why? |
| Transplants | 1 | 2020 | 136 | 0.74 | Why? |
| Protein-Losing Enteropathies | 1 | 2017 | 9 | 0.72 | Why? |
| Nephritis, Interstitial | 1 | 2019 | 83 | 0.72 | Why? |
| Lupus Nephritis | 1 | 2019 | 113 | 0.71 | Why? |
| Receptor Cross-Talk | 1 | 2017 | 21 | 0.70 | Why? |
| Kidney Failure, Chronic | 6 | 2020 | 3222 | 0.69 | Why? |
| Abatacept | 1 | 2019 | 192 | 0.68 | Why? |
| Fontan Procedure | 1 | 2017 | 42 | 0.68 | Why? |
| Transplantation Tolerance | 1 | 2016 | 13 | 0.66 | Why? |
| Th17 Cells | 2 | 2019 | 657 | 0.66 | Why? |
| Kidney Diseases | 2 | 2018 | 1434 | 0.62 | Why? |
| Biocompatible Materials | 1 | 2017 | 214 | 0.58 | Why? |
| Renal Insufficiency | 2 | 2020 | 810 | 0.57 | Why? |
| T-Lymphocytes, Regulatory | 2 | 2019 | 698 | 0.54 | Why? |
| Regeneration | 1 | 2017 | 429 | 0.54 | Why? |
| Immunocompromised Host | 5 | 2021 | 5150 | 0.52 | Why? |
| Rare Diseases | 1 | 2017 | 373 | 0.50 | Why? |
| Enzyme-Linked Immunospot Assay | 3 | 2018 | 325 | 0.47 | Why? |
| T-Lymphocyte Subsets | 1 | 2019 | 1387 | 0.44 | Why? |
| Histocompatibility | 3 | 2017 | 53 | 0.37 | Why? |
| T-Lymphocytes | 4 | 2019 | 6670 | 0.37 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2020 | 5277 | 0.36 | Why? |
| Nephrotic Syndrome | 2 | 2021 | 146 | 0.36 | Why? |
| B-Lymphocytes | 4 | 2021 | 4418 | 0.36 | Why? |
| Organ Transplantation | 2 | 2020 | 2616 | 0.35 | Why? |
| Drug Monitoring | 1 | 2016 | 1408 | 0.35 | Why? |
| Postoperative Complications | 3 | 2021 | 5861 | 0.34 | Why? |
| Histocompatibility Testing | 2 | 2017 | 219 | 0.31 | Why? |
| North America | 2 | 2020 | 1400 | 0.30 | Why? |
| Immunity, Humoral | 1 | 2020 | 4849 | 0.30 | Why? |
| Patient Selection | 1 | 2020 | 4560 | 0.29 | Why? |
| Renal Dialysis | 2 | 2020 | 4358 | 0.28 | Why? |
| Interferon-gamma Release Tests | 2 | 2017 | 253 | 0.27 | Why? |
| Clinical Trials as Topic | 2 | 2020 | 7330 | 0.24 | Why? |
| Biological Products | 1 | 2017 | 2331 | 0.23 | Why? |
| Acute Kidney Injury | 2 | 2020 | 5762 | 0.22 | Why? |
| Preoperative Period | 2 | 2019 | 271 | 0.22 | Why? |
| Allografts | 3 | 2019 | 761 | 0.22 | Why? |
| Mice, Inbred MRL lpr | 1 | 2019 | 9 | 0.20 | Why? |
| Epoetin Alfa | 1 | 2019 | 13 | 0.20 | Why? |
| Aristolochic Acids | 1 | 2019 | 23 | 0.20 | Why? |
| Proto-Oncogene Proteins c-fyn | 1 | 2018 | 4 | 0.20 | Why? |
| Postoperative Period | 2 | 2019 | 651 | 0.20 | Why? |
| CD57 Antigens | 1 | 2019 | 96 | 0.20 | Why? |
| Receptors, Interleukin | 1 | 2019 | 83 | 0.19 | Why? |
| Microfilament Proteins | 1 | 2018 | 45 | 0.19 | Why? |
| Antilymphocyte Serum | 1 | 2019 | 80 | 0.19 | Why? |
| Interleukin-1 Receptor-Associated Kinases | 1 | 2019 | 56 | 0.19 | Why? |
| Chemokine CXCL9 | 1 | 2019 | 154 | 0.19 | Why? |
| Phosphorylation | 2 | 2019 | 1060 | 0.18 | Why? |
| Immunosenescence | 1 | 2020 | 169 | 0.18 | Why? |
| Calcineurin Inhibitors | 1 | 2019 | 218 | 0.17 | Why? |
| Bioengineering | 1 | 2017 | 72 | 0.17 | Why? |
| Drug Dosage Calculations | 1 | 2019 | 243 | 0.17 | Why? |
| Delayed Graft Function | 1 | 2017 | 52 | 0.17 | Why? |
| Albuminuria | 1 | 2018 | 164 | 0.17 | Why? |
| Primary Cell Culture | 1 | 2019 | 501 | 0.17 | Why? |
| Colchicine | 2 | 2021 | 730 | 0.16 | Why? |
| Macrophage Activation | 1 | 2019 | 315 | 0.16 | Why? |
| International Cooperation | 2 | 2020 | 3436 | 0.16 | Why? |
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2019 | 290 | 0.16 | Why? |
| Transplantation, Autologous | 1 | 2017 | 364 | 0.16 | Why? |
| Kidney | 3 | 2019 | 3648 | 0.15 | Why? |
| Tissue Scaffolds | 1 | 2017 | 174 | 0.15 | Why? |
| Drug Substitution | 1 | 2019 | 385 | 0.15 | Why? |
| Rituximab | 2 | 2021 | 1096 | 0.15 | Why? |
| Renin-Angiotensin System | 1 | 2011 | 3661 | 0.15 | Why? |
| Pandemics | 12 | 2020 | 389249 | 0.15 | Why? |
| Humans | 36 | 2021 | 930598 | 0.15 | Why? |
| Fibrosis | 1 | 2019 | 800 | 0.14 | Why? |
| Transplantation, Homologous | 1 | 2017 | 757 | 0.14 | Why? |
| Angiotensin Receptor Antagonists | 1 | 2011 | 3892 | 0.14 | Why? |
| CD8-Positive T-Lymphocytes | 3 | 2020 | 5837 | 0.14 | Why? |
| Interleukin-17 | 1 | 2019 | 602 | 0.13 | Why? |
| Follow-Up Studies | 4 | 2021 | 17020 | 0.13 | Why? |
| Programmed Cell Death 1 Receptor | 1 | 2019 | 724 | 0.13 | Why? |
| Interleukin-1beta | 1 | 2019 | 992 | 0.13 | Why? |
| Opportunistic Infections | 1 | 2020 | 602 | 0.13 | Why? |
| Europe | 2 | 2020 | 12702 | 0.13 | Why? |
| Biomarkers | 6 | 2019 | 23361 | 0.13 | Why? |
| Peritoneal Fibrosis | 1 | 2011 | 4 | 0.12 | Why? |
| Betacoronavirus | 7 | 2020 | 204454 | 0.12 | Why? |
| Mice, Transgenic | 1 | 2019 | 2739 | 0.11 | Why? |
| Mice | 4 | 2019 | 21357 | 0.11 | Why? |
| Renal Replacement Therapy | 1 | 2020 | 1530 | 0.11 | Why? |
| Male | 19 | 2021 | 367725 | 0.11 | Why? |
| Retrospective Studies | 7 | 2021 | 105322 | 0.11 | Why? |
| DNA | 1 | 2016 | 778 | 0.10 | Why? |
| Interferon-gamma | 2 | 2018 | 2711 | 0.10 | Why? |
| Female | 18 | 2021 | 380317 | 0.10 | Why? |
| Immunologic Memory | 2 | 2019 | 3362 | 0.10 | Why? |
| Middle Aged | 14 | 2021 | 270681 | 0.10 | Why? |
| Predictive Value of Tests | 4 | 2019 | 9537 | 0.10 | Why? |
| Prospective Studies | 6 | 2020 | 43301 | 0.09 | Why? |
| Aged | 12 | 2021 | 215776 | 0.09 | Why? |
| Pneumonia, Viral | 7 | 2020 | 243684 | 0.09 | Why? |
| Adaptive Immunity | 1 | 2020 | 2585 | 0.09 | Why? |
| Coronavirus Infections | 7 | 2020 | 253789 | 0.09 | Why? |
| Adult | 14 | 2021 | 244371 | 0.09 | Why? |
| Membrane Proteins | 1 | 2018 | 1733 | 0.09 | Why? |
| Cells, Cultured | 1 | 2019 | 5835 | 0.09 | Why? |
| Gene Expression Profiling | 1 | 2019 | 3788 | 0.09 | Why? |
| Time Factors | 4 | 2020 | 31397 | 0.09 | Why? |
| Animals | 6 | 2020 | 78931 | 0.09 | Why? |
| Flow Cytometry | 1 | 2016 | 2393 | 0.08 | Why? |
| Comorbidity | 3 | 2020 | 34796 | 0.08 | Why? |
| Risk Assessment | 4 | 2020 | 25439 | 0.08 | Why? |
| Tissue and Organ Procurement | 1 | 2017 | 1277 | 0.08 | Why? |
| Acute Disease | 1 | 2019 | 6029 | 0.08 | Why? |
| Transcriptome | 1 | 2019 | 3466 | 0.08 | Why? |
| Risk | 1 | 2018 | 5288 | 0.07 | Why? |
| Registries | 3 | 2020 | 12327 | 0.07 | Why? |
| Immunity | 1 | 2017 | 2651 | 0.07 | Why? |
| Internationality | 1 | 2018 | 3297 | 0.07 | Why? |
| Biopsy | 3 | 2019 | 2811 | 0.07 | Why? |
| Immunologic Factors | 1 | 2021 | 4206 | 0.07 | Why? |
| Societies, Medical | 1 | 2020 | 6907 | 0.07 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2019 | 4545 | 0.07 | Why? |
| Mice, Knockout | 2 | 2019 | 1815 | 0.06 | Why? |
| Forecasting | 1 | 2017 | 4492 | 0.06 | Why? |
| Treatment Outcome | 6 | 2021 | 51732 | 0.06 | Why? |
| Glomerular Filtration Rate | 2 | 2018 | 1262 | 0.06 | Why? |
| Vaccines | 1 | 2021 | 3692 | 0.06 | Why? |
| Immunity, Innate | 1 | 2020 | 6570 | 0.06 | Why? |
| Azotemia | 1 | 2020 | 18 | 0.05 | Why? |
| Poliovirus Vaccine, Inactivated | 1 | 2021 | 72 | 0.05 | Why? |
| Disease Models, Animal | 1 | 2019 | 10998 | 0.05 | Why? |
| Recurrence | 2 | 2021 | 3675 | 0.05 | Why? |
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2021 | 91 | 0.05 | Why? |
| Citrobacter rodentium | 1 | 2019 | 11 | 0.05 | Why? |
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2019 | 24 | 0.05 | Why? |
| Metabolism | 1 | 2020 | 74 | 0.05 | Why? |
| src Homology Domains | 1 | 2018 | 8 | 0.05 | Why? |
| Mice, 129 Strain | 1 | 2018 | 36 | 0.05 | Why? |
| Actin Cytoskeleton | 1 | 2018 | 30 | 0.05 | Why? |
| Child | 5 | 2021 | 70012 | 0.05 | Why? |
| Enhancer Elements, Genetic | 1 | 2018 | 48 | 0.05 | Why? |
| Cobicistat | 1 | 2020 | 172 | 0.05 | Why? |
| Hyperkalemia | 1 | 2020 | 140 | 0.05 | Why? |
| Cytokines | 3 | 2020 | 15010 | 0.04 | Why? |
| Podocytes | 1 | 2018 | 82 | 0.04 | Why? |
| Mycophenolic Acid | 1 | 2020 | 383 | 0.04 | Why? |
| Risk Factors | 5 | 2020 | 71621 | 0.04 | Why? |
| Oligonucleotide Array Sequence Analysis | 1 | 2019 | 343 | 0.04 | Why? |
| Mice, Inbred C57BL | 2 | 2019 | 5542 | 0.04 | Why? |
| Homozygote | 1 | 2018 | 230 | 0.04 | Why? |
| Ubiquitination | 1 | 2019 | 343 | 0.04 | Why? |
| Gene Knockdown Techniques | 1 | 2018 | 347 | 0.04 | Why? |
| Interleukin-15 | 1 | 2018 | 169 | 0.04 | Why? |
| Plasma Cells | 1 | 2020 | 464 | 0.04 | Why? |
| Tacrolimus | 1 | 2020 | 435 | 0.04 | Why? |
| Global Health | 1 | 2020 | 13911 | 0.04 | Why? |
| T-Lymphocytes, Helper-Inducer | 1 | 2020 | 497 | 0.04 | Why? |
| Darunavir | 1 | 2020 | 477 | 0.04 | Why? |
| Colitis | 1 | 2019 | 266 | 0.04 | Why? |
| United States | 2 | 2020 | 46150 | 0.04 | Why? |
| Aged, 80 and over | 3 | 2021 | 88759 | 0.04 | Why? |
| Allergy and Immunology | 1 | 2019 | 240 | 0.04 | Why? |
| RNA, Small Interfering | 1 | 2018 | 817 | 0.03 | Why? |
| Chi-Square Distribution | 1 | 2017 | 961 | 0.03 | Why? |
| Stem Cell Transplantation | 1 | 2019 | 531 | 0.03 | Why? |
| Cell Differentiation | 1 | 2019 | 1338 | 0.03 | Why? |
| Inflammation | 3 | 2020 | 13255 | 0.03 | Why? |
| Printing, Three-Dimensional | 1 | 2019 | 624 | 0.03 | Why? |
| Young Adult | 5 | 2021 | 93724 | 0.03 | Why? |
| NF-kappa B | 1 | 2019 | 1301 | 0.03 | Why? |
| Child, Preschool | 3 | 2021 | 36283 | 0.03 | Why? |
| Protective Factors | 1 | 2017 | 1720 | 0.03 | Why? |
| Severity of Illness Index | 1 | 2019 | 48226 | 0.03 | Why? |
| Drug Combinations | 1 | 2020 | 3852 | 0.03 | Why? |
| Sequence Analysis, RNA | 1 | 2019 | 2290 | 0.03 | Why? |
| Kaplan-Meier Estimate | 1 | 2019 | 4260 | 0.02 | Why? |
| Area Under Curve | 1 | 2017 | 2564 | 0.02 | Why? |
| Adolescent | 4 | 2021 | 86841 | 0.02 | Why? |
| Tissue Donors | 1 | 2018 | 1679 | 0.02 | Why? |
| Genomics | 1 | 2019 | 3118 | 0.02 | Why? |
| Macrophages | 1 | 2019 | 2784 | 0.02 | Why? |
| Cardiovascular Diseases | 1 | 2011 | 11497 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2017 | 5440 | 0.02 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.02 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2018 | 3607 | 0.02 | Why? |
| Odds Ratio | 1 | 2017 | 5861 | 0.02 | Why? |
| Ritonavir | 1 | 2020 | 4212 | 0.02 | Why? |
| Influenza Vaccines | 1 | 2021 | 2941 | 0.02 | Why? |
| ROC Curve | 1 | 2017 | 6024 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2017 | 6543 | 0.02 | Why? |
| Asymptomatic Diseases | 1 | 2017 | 3444 | 0.02 | Why? |
| Renal Insufficiency, Chronic | 1 | 2018 | 2654 | 0.02 | Why? |
| Immunity, Cellular | 1 | 2017 | 3614 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2017 | 7220 | 0.01 | Why? |
| Logistic Models | 1 | 2017 | 9089 | 0.01 | Why? |
| Signal Transduction | 1 | 2018 | 7207 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2020 | 10649 | 0.01 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 9335 | 0.01 | Why? |
| Age Factors | 1 | 2020 | 21039 | 0.01 | Why? |
| Infant | 1 | 2021 | 30274 | 0.01 | Why? |
| Incidence | 1 | 2020 | 25622 | 0.01 | Why? |
| Cohort Studies | 1 | 2020 | 36005 | 0.01 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.01 | Why? |
| Italy | 1 | 2020 | 38444 | 0.01 | Why? |
| Prognosis | 1 | 2018 | 32490 | 0.01 | Why? |
| Hospitalization | 1 | 2021 | 54280 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2017 | 53120 | 0.01 | Why? |
| Antibodies, Viral | 1 | 2020 | 51949 | 0.01 | Why? |
Cravedi's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(219)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(134)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_